DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Effectiveness of Candesartan and Telmisartan on Morning Hypertension in Japanese Obese Patients

Information source: Saitama Medical University
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Hypertension

Intervention: Candesartan (Drug); Telmisartan (Drug)

Phase: N/A

Status: Recruiting

Sponsored by: Saitama Medical University

Official(s) and/or principal investigator(s):
Hidetomo Nakamoto, MD, Principal Investigator, Affiliation: Saitama Medical School Department of Renal Medicine

Overall contact:
Hidetomo Nakamoto, MD, Phone: +81-0492-76-1258, Email: nakamo_h@saitama-med.ac.jp

Summary

To investigate the effects of Candesartan and Telmisartan on the home blood pressure, glucose and lipid-metabolism in the hypertensive patients with the accumulation of visceral fat by the newly developed Tele-medicine system

Clinical Details

Official title: A Randomized, Comparative Study of the Effects of Candesartan and Telmisartan on the Home Blood Pressure, Glucose and Lipid Metabolism in the Hypertensive Patients With the Accumulation of Visceral Fat by the Central Registration System

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment

Primary outcome: Home blood pressure in the early morning

Secondary outcome:

Home blood pressure at bedtime

M/E ratio

Casual blood pressure

Body fat percentage

Body weight

Height

BMI

Blood potassium

Total cholesterol

HDL cholesterol

LDL cholesterol

Triglyceride

Blood glucose

IRI

HbAlc*

HOMA-IR

Urinary trace albumin

Creatinine

Detailed description: A randomized, comparative study of the effects of Candesartan and Telmisartan on the home blood pressure, glucose and lipid metabolism in the hypertensive patients with the accumulation of visceral fat by the central registration system

Eligibility

Minimum age: 20 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Circumference at waist: male ≧85 cm, female ≧90 cm

- Hypertensive patient with untreated hypertension, and casual blood pressure of

systole ≧140 mmHg, or diastole ≧90 mmHg

- Hypertensive patient with hypertension under treatment, and casual blood pressure of

systole ≧130 mmHg, or diastole ≧85 mmHg Exclusion Criteria:

- Significant hypertensive patient with diastolic blood pressure ≧120 mmHg

- Malignant hypertensive patient

- Patient with a contraindication to the study drugs (hypersensitivity, significant

hepatic diseases, pregnant woman)

- Patient with urinary protein (qualitative) +~++

- Patient with familial hyperlipidemia

- Other patients judged as ineligible for the study

Locations and Contacts

Hidetomo Nakamoto, MD, Phone: +81-0492-76-1258, Email: nakamo_h@saitama-med.ac.jp

Saitama Medical School Department of Renal Medicine, Saitama City, Saitama 350-0495, Japan; Recruiting
Hidetomo Nakamoto, MD, Phone: +81-492-76-1258, Email: nakamo_h@saitama-med.ac.jp
Hidetomo Nakamoto, MD, Principal Investigator
Additional Information

Starting date: February 2006
Last updated: January 9, 2007

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017